Piper Sandler and Bernstein Bullish on Roivant Sciences (ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 10 Best Medical Stocks to Buy Under $30. On April 16, Piper Sandler assumed coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Overweight rating on the stock and $40 price target.

Piper Sandler said the stock has gained more than 190% over the past year, supported by positive data and execution across brepocitinib’s development in dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. The research firm believes that brepocitinib has multi-blockbuster opportunities. It expects a possible dermatomyositis approval in the third quarter of 2026, Phase 3 CLARITY non-infectious uveitis (NIU) data in the second half of 2026, and the start of a Phase 3 study for cutaneous sarcoidosis by year-end 2026. Piper Sandler also pointed to expansion into lichen planopilaris.

Piper Sandler and Bernstein Bullish on Roivant Sciences (ROIV)

Earlier, on March 20, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a price target of $35.

The research firm highlighted potential upside from upcoming readouts in Pulmonary Hypertension associated with Interstitial Lung Disease and Non-Infectious Uveitis. Despite this, Bernstein pointed to key risks, including negative results for brepocitinib if Vygart Phase 3 in Dermatomyositis seems better and a softer-than-expected launch for brepocitinib. The research firm noted that these risks are already appropriately discounted.

Roivant Sciences Ltd. (NASDAQ:ROIV) is an American biopharmaceutical company that focuses on improving drug development and commercialization through innovative technology. The company operates a unique model where it creates subsidiaries, known as “Vants,” to develop and commercialize a variety of medicines and technologies.

While we acknowledge the risk and potential of ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ROIV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Fintech Stocks to Invest In According to Billionaires and 10 Unrivaled Stocks of the Next 5 Years.

Disclosure: None.  Follow Insider Monkey on Google News.